主营介绍

  • 产品类型:

    药品、医疗器械

  • 产品名称:

    注射用美罗培南 注射用头孢米诺钠 医疗器械

  • 经营范围:

    制造、销售(限本企业自产药品)片剂、硬胶囊剂(含抗肿瘤药)、颗粒剂、小容量注射剂、大容量注射剂、粉针剂(含头孢菌素类)及原料药(按许可证核定的产品项目从事生产经营),普通货运、危险货物运输(第2类第1、2项,第3类,第4类第1、2项,第5类第1项,第8类),生产、销售饲料添加剂、食品添加剂,销售五金、交电、化工产品及原料(不含化学危险品)、百货,建筑材料、装饰材料(不含危险化学品),钢材、木材、电器机械及器材、普通机械,制药技术咨询及转让,货物及技术进出口。

运营业务数据

最新公告日期:2018-04-21 
业务名称 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31
医药制造、药品流通产量(元) 1.08亿 1.05亿 - - -
医药制造、药品流通销量(元) 21.46亿 20.70亿 - - -
原料药(主要产品)销量(吨) - - 4690.00 7528.00 -
原料药(主要产品)产量(吨) - - 6936.00 8730.00 -
原料药(主要产品)销量(T) - - - - 8247.00
原料药(主要产品)产量(T) - - - - 8447.00

主营构成分析

{"2018-06-30":{"YYSR":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","69444.69"],["\u836f\u54c1\u5236\u9020\u4e1a","36096.72"]],"2":[["\u5236\u5242\u836f","36096.72"],["\u836f\u54c1","34830.52"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","34432.53"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","181.63"]],"3":[["\u56fd\u5185","105541.40"]]},"YYCB":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","60132.80"],["\u836f\u54c1\u5236\u9020\u4e1a","4744.06"]],"2":[["\u5236\u5242\u836f","4744.06"],["\u836f\u54c1","32279.19"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","27712.79"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","140.81"]],"3":[["\u56fd\u5185","64876.85"]]},"LRBL":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","22.90"],["\u836f\u54c1\u5236\u9020\u4e1a","77.10"]],"2":[["\u5236\u5242\u836f","77.10"],["\u836f\u54c1","6.27"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","16.52"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","0.10"]],"3":[["\u56fd\u5185","100.00"]]}},"2017-12-31":{"YYSR":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","171682.50"],["\u836f\u54c1\u5236\u9020\u4e1a","41667.19"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","85467.70"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","84231.32"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","41667.19"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","1983.49"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","213349.69"],["\u56fd\u5916",""]]},"YYCB":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","151369.36"],["\u836f\u54c1\u5236\u9020\u4e1a","6010.10"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","70516.84"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","77746.65"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","6010.10"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","3105.87"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","157379.46"],["\u56fd\u5916",""]]},"LRBL":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","36.29"],["\u836f\u54c1\u5236\u9020\u4e1a","63.71"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","26.71"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","11.59"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","63.71"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","-2.01"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","100.00"],["\u56fd\u5916",""]]}},"2017-06-30":{"YYSR":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","86243.29"],["\u836f\u54c1\u5236\u9020\u4e1a","18248.25"]],"2":[["\u836f\u54c1","48292.99"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","37750.98"],["\u5236\u5242\u836f","18248.25"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","199.33"]],"3":[["\u56fd\u5185","104491.54"]]},"YYCB":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","76337.41"],["\u836f\u54c1\u5236\u9020\u4e1a","5107.25"]],"2":[["\u836f\u54c1","45880.01"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","30329.91"],["\u5236\u5242\u836f","5107.25"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","127.49"]],"3":[["\u56fd\u5185","81444.66"]]},"LRBL":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","42.98"],["\u836f\u54c1\u5236\u9020\u4e1a","57.02"]],"2":[["\u836f\u54c1","10.47"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","32.20"],["\u5236\u5242\u836f","57.02"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","0.31"]],"3":[["\u56fd\u5185","100.00"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u836f\u54c1\u6d41\u901a\u4e1a","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[69444.69,171682.5,86243.29],"columnData":[65.8,80.47,82.54],"unit":["6.94\u4ebf","17.17\u4ebf","8.62\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020\u4e1a","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[36096.72,41667.19,18248.25],"columnData":[34.2,19.53,17.46],"unit":["3.61\u4ebf","4.17\u4ebf","1.82\u4ebf"]}],"chartWrap2":[{"name":"\u5236\u5242\u836f","timeData":["2018-06-30","2017-06-30"],"lineData":[36096.72,18248.25],"columnData":[34.2,17.46],"unit":["3.61\u4ebf","1.82\u4ebf"]},{"name":"\u836f\u54c1","timeData":["2018-06-30","2017-06-30"],"lineData":[34830.52,48292.99],"columnData":[33,46.22],"unit":["3.48\u4ebf","4.83\u4ebf"]},{"name":"\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2018-06-30","2017-06-30"],"lineData":[34432.53,37750.98],"columnData":[32.62,36.13],"unit":["3.44\u4ebf","3.78\u4ebf"]},{"name":"\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[181.63,1983.49,199.33],"columnData":[0.17,0.93,0.19],"unit":["181.63\u4e07","1983.49\u4e07","199.33\u4e07"]},{"name":"\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-12-31"],"lineData":[85467.7],"columnData":[40.06],"unit":["8.55\u4ebf"]},{"name":"\u836f\u54c1\u6d41\u901a-\u836f\u54c1","timeData":["2017-12-31"],"lineData":[84231.32],"columnData":[39.48],"unit":["8.42\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","timeData":["2017-12-31"],"lineData":[41667.19],"columnData":[19.53],"unit":["4.17\u4ebf"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[105541.4,213349.69,104491.54],"columnData":[100,100,100],"unit":["10.55\u4ebf","21.33\u4ebf","10.45\u4ebf"]},{"name":"\u56fd\u5916","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}]},"YYCB":{"chartWrap1":[{"name":"\u836f\u54c1\u6d41\u901a\u4e1a","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[60132.8,151369.36,76337.41],"columnData":[92.69,96.18,93.73],"unit":["6.01\u4ebf","15.14\u4ebf","7.63\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020\u4e1a","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[4744.06,6010.1,5107.25],"columnData":[7.31,3.82,6.27],"unit":["4744.06\u4e07","6010.10\u4e07","5107.25\u4e07"]}],"chartWrap2":[{"name":"\u5236\u5242\u836f","timeData":["2018-06-30","2017-06-30"],"lineData":[4744.06,5107.25],"columnData":[7.31,6.27],"unit":["4744.06\u4e07","5107.25\u4e07"]},{"name":"\u836f\u54c1","timeData":["2018-06-30","2017-06-30"],"lineData":[32279.19,45880.01],"columnData":[49.75,56.33],"unit":["3.23\u4ebf","4.59\u4ebf"]},{"name":"\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2018-06-30","2017-06-30"],"lineData":[27712.79,30329.91],"columnData":[42.72,37.24],"unit":["2.77\u4ebf","3.03\u4ebf"]},{"name":"\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[140.81,3105.87,127.49],"columnData":[0.22,1.97,0.16],"unit":["140.81\u4e07","3105.87\u4e07","127.49\u4e07"]},{"name":"\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-12-31"],"lineData":[70516.84],"columnData":[44.81],"unit":["7.05\u4ebf"]},{"name":"\u836f\u54c1\u6d41\u901a-\u836f\u54c1","timeData":["2017-12-31"],"lineData":[77746.65],"columnData":[49.4],"unit":["7.77\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","timeData":["2017-12-31"],"lineData":[6010.1],"columnData":[3.82],"unit":["6010.10\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[64876.85,157379.46,81444.66],"columnData":[100,100,100],"unit":["6.49\u4ebf","15.74\u4ebf","8.14\u4ebf"]},{"name":"\u56fd\u5916","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}]},"LRBL":{"chartWrap1":[{"name":"\u836f\u54c1\u6d41\u901a\u4e1a","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[22.9,36.29,42.98],"columnData":[22.9,36.29,42.98],"unit":["22.90\u4e07","36.29\u4e07","42.98\u4e07"]},{"name":"\u836f\u54c1\u5236\u9020\u4e1a","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[77.1,63.71,57.02],"columnData":[77.1,63.71,57.02],"unit":["77.10\u4e07","63.71\u4e07","57.02\u4e07"]}],"chartWrap2":[{"name":"\u5236\u5242\u836f","timeData":["2018-06-30","2017-06-30"],"lineData":[77.1,57.02],"columnData":[77.1,57.02],"unit":["77.10\u4e07","57.02\u4e07"]},{"name":"\u836f\u54c1","timeData":["2018-06-30","2017-06-30"],"lineData":[6.27,10.47],"columnData":[6.27,10.47],"unit":["6.27\u4e07","10.47\u4e07"]},{"name":"\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2018-06-30","2017-06-30"],"lineData":[16.52,32.2],"columnData":[16.52,32.2],"unit":["16.52\u4e07","32.20\u4e07"]},{"name":"\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[0.1,-2.01,0.31],"columnData":[0.1,-2.01,0.31],"unit":["1000.00","-2.01\u4e07","3100.00"]},{"name":"\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-12-31"],"lineData":[26.71],"columnData":[26.71],"unit":["26.71\u4e07"]},{"name":"\u836f\u54c1\u6d41\u901a-\u836f\u54c1","timeData":["2017-12-31"],"lineData":[11.59],"columnData":[11.59],"unit":["11.59\u4e07"]},{"name":"\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","timeData":["2017-12-31"],"lineData":[63.71],"columnData":[63.71],"unit":["63.71\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[100,100,100],"columnData":[100,100,100],"unit":["100.00\u4e07","100.00\u4e07","100.00\u4e07"]},{"name":"\u56fd\u5916","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 药品流通业 6.94亿 65.80% 6.01亿 92.69% 22.90% 13.41%
药品制造业 3.61亿 34.20% 4744.06万 7.31% 77.10% 86.86%
按产品 制剂药 3.61亿 34.20% 4744.06万 7.31% 77.10% 86.86%
药品 3.48亿 33.00% 3.23亿 49.75% 6.27% 7.32%
医疗器械及试剂 3.44亿 32.62% 2.77亿 42.72% 16.52% 19.52%
商品及材料销售 181.63万 0.17% 140.81万 0.22% 0.10% 22.48%
按地区 国内 10.55亿 100.00% 6.49亿 100.00% 100.00% 38.53%

董事会经营评述

  一、概述  近年来,随着医药行业政策、法规制度的陆续出台和持续推进,国内医药行业正驶入规范发展的快车道,给国内医药企业带来了重大的机遇和挑战。从行业基本面上来看,医药行业的发展方向已经比较明确。上游原料药行业受环保政策压力影响继续清除落后产能,中游制剂研发在政策上实行优化审评、鼓励创新,制剂生产领域持续推进一致性评价工作,实现优胜劣汰和进口替代;下游医药流通两票制持续推进,将促进行业集中度的提升,医院严控药占比、分级诊疗等也将推动医改的持续深化。  面对当前医药行业的新形势,公司精心谋划,积极应对,确立了"外延重收购兼并、内生重医药工业"的发展战略及"在三年内,公司利润、市值规模实现翻番"... 查看全部▼

  一、概述
  近年来,随着医药行业政策、法规制度的陆续出台和持续推进,国内医药行业正驶入规范发展的快车道,给国内医药企业带来了重大的机遇和挑战。从行业基本面上来看,医药行业的发展方向已经比较明确。上游原料药行业受环保政策压力影响继续清除落后产能,中游制剂研发在政策上实行优化审评、鼓励创新,制剂生产领域持续推进一致性评价工作,实现优胜劣汰和进口替代;下游医药流通两票制持续推进,将促进行业集中度的提升,医院严控药占比、分级诊疗等也将推动医改的持续深化。
  面对当前医药行业的新形势,公司精心谋划,积极应对,确立了"外延重收购兼并、内生重医药工业"的发展战略及"在三年内,公司利润、市值规模实现翻番"的战略目标。为保证战略目标的达成,我们将在以下两方面持续发力:一方面,公司将通过加大原有产品一致性评价的投入,努力优化产品结构,提高核心产品的市场占有率;并通过借助大股东旗下方正医药研究院强大的研发实力实现高端新产品引入和项目技术合作,从而丰富公司产品储备,增强盈利能力,改善盈利结构,力争用三年时间实现公司业绩在2018年基础上再翻一倍。
  另一方面,公司将充分发挥北大医疗旗下唯一上市平台的影响力和资源整合力,聚集资源与资本,力争在三年时间内并购一到两家体量超过现有上市公司盈利规模的医药或医疗优质资产。以进一步提升公司市值及行业地位,使公司尽快迈入中国医药医疗服务第一阵营。
  2018年上半年,公司在"抓项目、调结构、结硬寨、打呆仗"新的经营理念指导下,不再盲目追求营业收入增长的表面繁荣,紧紧咬住利润增长这一关键指标,进一步夯实营销结构,集中精力重点发展医药工业,优化医药商业,使得公司主营业务和盈利结构得到进一步优化。报告期内,公司实现营业收入105,988.03万元,其中,公司医药工业上半年度实现营业收入3.61亿元,较上年同期增长97.81%,运营成本却下降了7.11%。正是因为这样的调整,使得归属于母公司股东的净利润实现2,672.72万元,较上年同期增长25.67%。截至2018年6月30日,公司资产总额为210,951.98万元;归属于母公司股东的净资产为119,485.71万元;报告期内公司经营活动产生的现金流量净额为3,233.13万元,较上年同期增长145.26%,经营质量进一步改善,实现了2018年上半年度的调结构,重医药工业战略。
  医药工业方面:报告期内,公司狠抓医药工业改革,积极开展产品仿制药质量和疗效一致性评价工作;深入挖掘新老产品潜力,促成产品结构优化、调整;同时大力加强新产品市场拓展,老产品维稳上量工作。期内医药工业保持快速增长,重点产品取得新的突破,销量稳步上升,产品盈利结构得到持续改善。报告期内,医药工业实现主营业务收入同比增长97.81%;净利润(剔除财政扶持资金补助影响)同比增长182%。公司在不断夯实基础,做好内生业绩增长的同时,密切关注外部优质产品的并购机会,2018年上半年,公司确定了多个具有良好市场前景的合作项目,涉及风湿骨科领域及心脑血管领域,项目的落地将会进一步丰富公司的产品线,为未来业绩的提升奠定良好的产品结构。
  医药流通方面:报告期内,公司稳定并推进北大医药武汉公司的配送业务以及北京北医医药的供应链管理业务,同时持续拓展北京和湖北两地业务;随着医改政策持续不断地推进,为应对市场的不断变化,在扩大集中配送、医药药房托管优质资源的同时,公司加强了对流通业务的梳理、整合,集中主要精力服务优质资源,业务毛利率同比上升。
报告期内,医药流通业务实现主营业务收入6.94亿,同比下降19.5%,但医药流通业务整体毛利率较去年同期提升1.92%。

  二、公司面临的风险和应对措施
  (1)质量控制风险
  仿制药一致性评价等相关法规政策的持续执行,对国内仿制药质量提出了更高的要求,同时也对药品研发、生产质量等流程提出了新的标准,一致性评价工作需要大量人力、物力和财力的投入,产品在规定期限内是否能够通过新标准还存在较大的不确定性。公司将严格按照GMP规范要求,建立全流程质量把控,认真完成仿制药一致性评价工作,切实保障药品质量,建立良好的信誉与口碑。
  (2)原料涨价及药品降价风险
  近年来,上游原料药行业受环保投入加大、车间升级改造、人力成本增加等影响,从而加大了公司原料采购价格提升的风险;受医保控费、降低药占比等因素的影响,各地招投标价格下降压力越来越大,从而也加大了公司中标价降低的风险,对公司发展有不利影响。针对药品降价风险,公司将通过补充后续新产品、加大对现有产品的市场推广力度来提升市场竞争力;与此同时,公司将积极关注产品引进和企业并购机会,并加大研发的力度和投入,以获取新的产品扩大销售规模。
  (3)药品招标政策风险
  2017年,新版国家医保目录落地,但各省份医保增补目录确定和执行情况尚不完全明确,公司招投标难度加大,药品未竞标成功将对公司业绩有不利影响。为减少相关风险,公司将努力推进现有产品进入各省份医保目录的增补工作,并加大产品学术推广力度,加强市场准入工作,力争产品在更多省份实现中标。
  (4)制剂研发风险
  制药行业具有高投入、长周期、高风险的特点,药品从药学研究、临床研究、获取药品注册批件,再到正式生产需要经过多重审批,在此过程中,任一环节的决策与技术出现问题必将会影响研发成果,因此存在不确定性风险。几年来,国家对药品注册监管日趋严格,进而增加了公司的研发风险。为减少研发的风险,公司在项目筛选上将加强立项把关,以市场容量大,制剂工艺成熟的仿制药为主。同时,积极跟踪国家政策导向,积极搭建高水平的研发团队,扎实做好研究工作。
  (5)管理风险
  随着公司转型初显成效,公司的管理与运营能力需要不断加强。在战略定位、资源整合、研发创新、制度调整等方面,公司同样面临更高的要求。公司在管理模式、激励机制、内部控制等方面若无法满足当下医药行业变革的要求,将会在内外部压力下承担更多风险。因此,公司将密切关注行业政策动向,适时进行战略更新,推进精细化管理,持续完善内控体系建设,建立良好的企业文化和激励机制,激活组织活力,借助信息化系统,全面提升组织运营管理能力和管控水平。

  三、核心竞争力分析
  公司现主要以制剂研发、生产、销售及医药流通等业务为主。
  (一)研发优势
公司拥有国家级化学合成药物研发技术中心,同时,公司依托北京大学医学院深厚的学术基底以及北大医疗产业集团旗下的方正医药研究院的优势研发资源,共同开展药品研发合作,实现了从创新药物研发到产品工艺技术革新的产品创新全覆盖,现已形成丰富的在研产品梯队,将有力保障后续产品供应,助力公司长远发展。
  (二)营销优势
  成熟的营销团队和营销网络是公司核心竞争力的重要组成部分。公司非常重视市场拓展和销售渠道的建设,制剂营销网络现已基本覆盖全国,并能在新政策形势下顺利进行合规运营;与此同时,公司还拥有分别以北京、湖北地区为核心的医药商业流通中心,其深度分销和配送服务已积蓄了丰富的经验和资源网络,其中,北医医药定位于服务北大医疗产业集团优势医疗资源的集采平台,并和武汉叶开泰均已形成成熟的盈利模式。
  (三)企业文化优势
  "创新、责任、信任、努力"的企业文化已成为推动各项工作的核心导向,具有积极向上的引导作用,公司综合竞争力得到进一步提升。
  公司将充分利用北京大学的品牌和资源,集中力量专注制剂研发、生产及销售,加强公司内生增长并适时推进外延发展,最终实现公司的战略目标。 收起▲